Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients.
OBJECTIVE
The purpose of this study was to investigate the co-expression of survivin, c-erbB2, and COX-2 in endometrial cancer tissues and evaluate its prognostic significance in endometrial cancer


METHODS
Tumor tissue biopsies from 110 patients with primary untreated endometrial carcinomas were studied by immunohistochemistry. Statistical analysis evaluated correlation of antigen expression with tumor stage, grade, myometrial invasion, and histologic type. Association with disease outcome was also investigated


RESULTS
The results showed that expression of the three antigens was independently associated with histological grade, disease stage, and myometrial invasion. Clinicopathological parameters were also associated with the number of antigens expressed by each tumor, the expression of more antigens correlating with advanced stage disease and deep myometrial invasion. In a 10-year follow-up, patients with tumors expressing more of these three antigens had significantly lower survival rate that those with smaller expression score


CONCLUSIONS
Our results indicate that the co-expression score has independent prognostic value for endometrial cancer.
Lambropoulou
Maria
M
Laboratory of Histology-Embryology, Democritus University of Thrace, 68 100, Alexandroupolis, Greece.
Papadopoulos
Nikolaos
N
Tripsianis
Grigoris
G
Alexiadis
George
G
Pagonopoulou
Olga
O
Kiziridou
Anastasia
A
Liberis
Vassilios
V
Kakolyris
Stylianos
S
Chatzaki
Ekaterini
E
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000175:diagnosis* / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D016022:Case-Control Studies; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D016889:Endometrial Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000401:mortality* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins / Q000378:metabolism*; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D016019:Survival Analysis; D000077022:Survivin
D051546:Cyclooxygenase 2; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D000077022:Survivin; C107489:BIRC5 protein, human